To identify novel intermediate regulatory factors between SFRP2 and SOX2 we hypothesized that activity of such genes should increase or decrease upon SFRP2-overexpression but not upon SOX2-overexpression, and correlate with SOX2 expression in the CCLE glioma cell lines. This evidence concerns the gene SOX2 and central nervous system cancer.